Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - europepmc.org
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With
Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial …
[PDF] researchgate.net

[PDF][PDF] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer The ALTER 0303 Phase 3 …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng… - JAMA, 2018 - researchgate.net
OBJECTIVE To investigate the efficacy of anlotinib on overall survival of patients with
advanced NSCLC progressing after second-line or further treatment. DESIGN, SETTING …